



PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	)	Confirmation No.:	1157
	)		
<b>PILLARISETTI et al.</b>	)	Art Unit:	1644
	)		
Serial No.: 10/026,335	)	Examiner:	Saunders, David A.
	)		
Filed: December 21, 2001	)	Docket No.:	R18631 1030.1
	)		(51880.0006.2)
For: METHODS AND COMPOSITIONS	)		
FOR DETECTING COMPOUNDS	)		
THAT MODULATE	)		
INFLAMMATORY RESPONSES	)		

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop: AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The citation of information on the attached Form PTO/SB/08B, "Information Disclosure Statement By Applicant" is made pursuant to 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. §1.98, a copy of each cited item is enclosed.

The Examiner is specifically requested not to rely solely on the information submitted herein. On the contrary, the Examiner is requested to conduct an independent and thorough review of the information, and to form independent opinions as to their significance.

I hereby certify that all correspondences listed above are being deposited for delivery to the above addressee with the United States Postal Service, as First Class mail in an envelope with sufficient postage addressed to: Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on March 15, 2006.

Pam Turnbough  
(Printed Name of Person Mailing Correspondence)

  
(Signature of Person Mailing Correspondence)

WCSR 2054628v1


03/21/2006 DEMANU1 00000088 090528 10026335  
03 FC:1806 180.00 DA

It is respectfully requested that the Examiner initial and return a copy of the enclosed Form PTO/SB/08B and to indicate in the official file wrapper of the above-identified patent application that each item of the cited information has been considered.

The citation of this information does not constitute an admission that any of the materials are available as a reference or of priority, or a waiver of any right applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to deposit account no. 09-0528.

Respectfully submitted,

  
\_\_\_\_\_  
David E. Wigley  
Reg. No. 52,362

Customer Number: **Applied For**  
Womble Carlyle Sandridge & Rice, PLLC  
P.O. Box 7037  
Atlanta, GA 30357-0037  
(404) 879-2433 (Telephone)  
(404) 879-2933 (Facsimile)

Docket No.: R18631 1030.1 (51880.0006.2)



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/026,335
Filing Date	December 21, 2001
First Named Inventor	Pillarisetti, S.
Art Unit	1644
Examiner Name	Saunders, David A.
Attorney Docket Number	R18631 1030.1 (51880.0006.2)

Sheet 1 of 1

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	MARUI, N. et al., Vascular Cell Adhesion Molecule-1 (VCAM-1) Gene Transcription and Expression are Regulated through an Antioxidant-sensitive Mechanism in Human Vascular Endothelial Cells, The American Society for Clinical Investigation, Inc., Oct. 1993, Vol. 92, 1866-1874	
	2	SCHRECK, R. et al., Dithiocarbamates as Potent Inhibitors of Nuclear Factor kB Activation in Intact Cells, J. Exp. Med., The Rockefeller University Press, May 1992, Vol. 175, 1181-1194	
	3	NEUMANN, A. et al., Pro-Inflammatory Effects of AGEs: AGE-Induced Transduction in Macrophages", Journal of the American Society of Nephrology, Sept. 2000, 485A, Vol. 11, American Society of Nephrology, U.S.A.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.